C‐Terminal Decarboxylation of Proline‐Derived Building Blocks for Protein‐Binding Peptides

Abstract

Using a set of conformationally restricted Proline‐derived Modules (ProMs), our group has recently succeeded in developing inhibitors for the enabled/vasodilator‐stimulated phosphoprotein homology 1 (EVH1) domain, which is a key mediator of cell migration and plays an important role in tumor metastasis. While these (formally) pentapeptidic compounds show nanomolecular binding affinities towards EVH1, their drug‐like properties and cell permea­bility need to be further optimized before they can be clinically tested as therapeutic agents against metastasis. In this study, we sought to improve these properties by removing the C‐terminal carboxylic acid function of our peptoids, either by late‐stage decarboxylation or by direct synthesis. For late‐stage decarboxy­lation of ProM‐like systems, a method for reductive halo decarboxylation was optimized and applied to several proline‐derived substrates. In this way, a series of new decarboxy ProMs suitable as building blocks for decarboxy EVH1 inhibitors were obtained. In addition, we incorporated decarboxy‐ProM‐1 into the penta­peptide‐like compound Ac[2‐Cl‐F][ProM‐2][Decarb‐ProM‐1], which showed similar affinity towards EVH1 as the methyl ester derivative (Ac[2‐Cl‐F][ProM‐2][ProM1]OMe). However, despite better calculated drug‐like properties, this compound did not inhibit chemotaxis in a cellular assay.